Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cyprumed GmbH manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This 1 action represents the current pending prosecution workload as reported in the data. The presence of this count reflects the interaction with the patent office for the current filing cycle.
The prosecution of this matter is handled by 1 distinct examiner working within 1 distinct art unit. This indicates that the company's active patent filings are not currently spread across more than the 1 art unit. For the practitioner, this concentration means that the outcome of the pending applications rests on this point of review. The number of art units suggests the technology falls within the scope of this 1 unit.
WISTNER, SARAH CLINKSCALES is identified as the busiest examiner for this portfolio. This examiner is responsible for 1 busiest examiner pending office action, which matches the total count of pending actions for the company. Because the busiest examiner pending count is 1, there is no distribution of work among other personnel. All current prosecution outcomes for Cyprumed GmbH are tied to this examiner's evaluation.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WISTNER, SARAH CLINKSCALES | 1 | 25.0% | +81.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043976 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | WISTNER, SARAH CLINKSCALES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043976 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | WISTNER, SARAH CLINKSCALES | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18043976 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | WISTNER, SARAH CLINKSCALES | 1616 | §103§112DP | Non-Final OA | — | Pending | Mar 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial